ATE551056T1 - Mittel zur hemmung der körpergewichtszunahme - Google Patents

Mittel zur hemmung der körpergewichtszunahme

Info

Publication number: ATE551056T1
Authority: AT; Austria
Prior art keywords: body weight; weight gain; agent; inhibiting body; provides
Prior art date: 2002-12-27

Application number

AT03768195T

Other languages

English (en)

Inventor

Zen-Ichi Terashita

Keiji Kusumoto

Fuminari Yamaguchi

Yoshimi Imura

Original Assignee

Takeda Pharmaceutical

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-12-27

Filing date

2003-12-25

Publication date

2012-04-15

2003-12-25 Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical

2012-04-15 Application granted granted Critical

2012-04-15 Publication of ATE551056T1 publication Critical patent/ATE551056T1/de

Links

230000037396 body weight Effects 0.000 title abstract 3
235000019786 weight gain Nutrition 0.000 title abstract 2
230000002401 inhibitory effect Effects 0.000 title 1
239000008177 pharmaceutical agent Substances 0.000 abstract 2
102000005862 Angiotensin II Human genes 0.000 abstract 1
101800000733 Angiotensin-2 Proteins 0.000 abstract 1
CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 abstract 1
102000000536 PPAR gamma Human genes 0.000 abstract 1
108010016731 PPAR gamma Proteins 0.000 abstract 1
230000001270 agonistic effect Effects 0.000 abstract 1
229950006323 angiotensin ii Drugs 0.000 abstract 1
230000003042 antagnostic effect Effects 0.000 abstract 1
150000001875 compounds Chemical class 0.000 abstract 1
206010012601 diabetes mellitus Diseases 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
230000000694 effects Effects 0.000 abstract 1
229940002612 prodrug Drugs 0.000 abstract 1
239000000651 prodrug Substances 0.000 abstract 1
150000003839 salts Chemical class 0.000 abstract 1
239000000126 substance Substances 0.000 abstract 1
230000001629 suppression Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4245—Oxadiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Obesity (AREA)
Diabetes (AREA)
Hematology (AREA)
Child & Adolescent Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Lubricants (AREA)
Registering, Tensioning, Guiding Webs, And Rollers Therefor (AREA)
Anti-Oxidant Or Stabilizer Compositions (AREA)
Plural Heterocyclic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT03768195T 2002-12-27 2003-12-25 Mittel zur hemmung der körpergewichtszunahme ATE551056T1 (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
JP2002380386		2002-12-27
PCT/JP2003/016656 WO2004060399A1 (ja)	2002-12-27	2003-12-25	体重増加抑制剤

Publications (1)

Publication Number	Publication Date
ATE551056T1 true ATE551056T1 (de)	2012-04-15

Family

ID=32708435

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT03768195T ATE551056T1 (de)	2002-12-27	2003-12-25	Mittel zur hemmung der körpergewichtszunahme

Country Status (8)

Country	Link
US (1)	US7582662B2 (de)
EP (1)	EP1579872B8 (de)
KR (1)	KR101092279B1 (de)
CN (1)	CN100438911C (de)
AT (1)	ATE551056T1 (de)
AU (1)	AU2003292775A1 (de)
CA (1)	CA2511737A1 (de)
WO (1)	WO2004060399A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SE0300988D0 (sv) *	2003-04-03	2003-04-03	Astrazeneca Ab	New use
TW200616625A (en) *	2004-10-07	2006-06-01	Takeda Pharmaceuticals Co	Agent for prophylaxis or treatment of metabolic syndrome
US20060084637A1 (en) *	2004-10-18	2006-04-20	Maria Alemany	Methods of using fatty-acid esters of estrogens and thermogenic compounds for reducing the body weight of a mammal and compositions containing the same
WO2008123536A1 (en) *	2007-03-28	2008-10-16	Takeda Pharmaceutical Company Limited	Solid pharmaceutical composition comprising a benzimidazole-7-carboxylate derivative and a ph control agent

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0914158B2 (de) *	1996-04-05	2006-01-25	Takeda Chemical Industries, Ltd.	Pharmazeutische kombination enthaltend einen wirkstoff mit angiotensin-ii antagonistischer aktivität und einen wirkstoff der die insulin-sensitivität erhöht
US6177587B1 (en) *	1997-05-26	2001-01-23	Takeda Chemical Industries, Ltd.	Production method of aminobenzene compound
JP3003030B2 (ja)	1997-05-26	2000-01-24	武田薬品工業株式会社	アミノベンゼン化合物の製造法
AU2745199A (en) *	1998-03-04	1999-09-20	Takeda Chemical Industries Ltd.	Sustained-release preparation for aii antagonist, production and use thereof
HUP0103714A3 (en) *	1998-05-11	2003-05-28	Takeda Pharmaceutical	Oxyiminoalkanoic acid derivatives with hypoglycemic and hypolipidemic activity, medicaments containing them and their use
CA2379666C (en)	1999-07-21	2009-10-13	Takeda Chemical Industries, Ltd.	Agent for preventing recurrence of cerebrovascular disorder and agent for ameliorating troubles following cerebrovascular disorder and inhibiting progress thereof
AU1303301A (en)	1999-11-10	2001-06-06	Takeda Chemical Industries Ltd.	Body weight gain inhibitors
WO2001060362A1 (fr)	2000-02-18	2001-08-23	Takeda Chemical Industries, Ltd.	INHIBITEURS DE TNF-$g(a)
WO2001060410A1 (en)	2000-02-21	2001-08-23	Takeda Chemical Industries, Ltd.	Sustained release preparations of physiologically active compound hardly soluble in water and production process and use of the same
CN1440283A (zh) *	2000-04-12	2003-09-03	诺瓦提斯公司	有机化合物的联合形式
US20030083342A1 (en) *	2002-08-27	2003-05-01	Steele Ronald Edward	Combination of organic compounds
HUP0301335A3 (en)	2000-04-12	2006-02-28	Novartis Ag	Combination of organic compounds
PE20020617A1 (es) *	2000-08-22	2002-08-05	Novartis Ag	Composicion que comprende un antagonista del receptor at1 y un potenciador de la secrecion de insulina o un sensibilizante a la insulina
CA2420055C (en) *	2000-08-25	2010-06-01	Takeda Chemical Industries, Ltd.	Fibrinogen-lowering agent
EP1369130A1 (de)	2001-03-16	2003-12-10	Takeda Chemical Industries, Ltd.	Verfahren zur herstellung eines präparats mit verzögerter freisetzung
US20040219208A1 (en)	2001-08-03	2004-11-04	Ryu Kawamura	Sustained-release medicines
EP1452176A4 (de) *	2001-12-03	2009-01-21	Takeda Pharmaceutical	Mittel zur verbesserung der insulinresistenz

2003
- 2003-12-25 KR KR1020057012069A patent/KR101092279B1/ko not_active Expired - Fee Related
- 2003-12-25 WO PCT/JP2003/016656 patent/WO2004060399A1/ja not_active Ceased
- 2003-12-25 CA CA002511737A patent/CA2511737A1/en not_active Abandoned
- 2003-12-25 US US10/540,369 patent/US7582662B2/en not_active Expired - Fee Related
- 2003-12-25 CN CNB2003801100435A patent/CN100438911C/zh not_active Expired - Fee Related
- 2003-12-25 EP EP03768195A patent/EP1579872B8/de not_active Expired - Lifetime
- 2003-12-25 AT AT03768195T patent/ATE551056T1/de active
- 2003-12-25 AU AU2003292775A patent/AU2003292775A1/en not_active Abandoned

Also Published As

Publication number	Publication date
HK1083587A1 (en)	2006-07-07
US7582662B2 (en)	2009-09-01
CN1756567A (zh)	2006-04-05
KR101092279B1 (ko)	2011-12-13
EP1579872B1 (de)	2012-03-28
WO2004060399A1 (ja)	2004-07-22
AU2003292775A1 (en)	2004-07-29
EP1579872A4 (de)	2006-03-22
EP1579872B8 (de)	2012-11-07
CA2511737A1 (en)	2004-07-22
CN100438911C (zh)	2008-12-03
EP1579872A1 (de)	2005-09-28
KR20050085905A (ko)	2005-08-29
US20060069133A1 (en)	2006-03-30

Publication	Publication Date	Title
MX2024007853A (es)	2024-07-09	Composicion farmaceutica que comprende un compuesto de quinazolina.
WO2003096990A3 (en)	2004-02-26	Protein cages for the delivery of medical imaging and therapy
DE60231407D1 (de)	2009-04-16	Hemmende antikörper der her3-aktivität
TNSN07208A1 (en)	2008-11-21	3,5-DISUBTITUTED AND 3,5,7-TRISUBSTITUTED-3H-OXAZOLO AND 3H-THIAZOLO [4,5-d] PYRIMIDIN-2-ONE COMPOUNDS AND PRODRUGS THEREOF
WO2006059234A3 (en)	2006-07-20	Bicyclic amides as kinase inhibitors
ATE442142T1 (de)	2009-09-15	Fredericamycin-derivate als arzneimittel zur tumorbehandlung
AP2004003069A0 (en)	2004-06-30	3-beta-d-ribofuranosynthiazolo [4-5-d] pyridimine nucleosides and uses thereof.
WO2004009558A3 (en)	2004-04-15	Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations
WO2002100390A3 (en)	2004-04-22	Improved method of treating the syndrome of coronary heart disease risk factors in humans
WO2005056524A3 (en)	2005-09-22	Therapeutic agents useful for treating pain
TNSN04203A1 (en)	2007-03-12	Benzoxazinone-derived compounds, their preparation and use as medicaments
BRPI0418099A (pt)	2007-04-17	compostos, composição farmacêutica, e uso de um composto
EA200600971A1 (ru)	2006-12-29	Применение замещённых 2 - аминотетралинов для профилактического лечения болезни паркинсона
ATE487720T1 (de)	2010-11-15	5,6,7,8-tetrahydropteridin-derivate als hsp90- hemmer
TR200101633T2 (tr)	2002-06-21	Farmasötik bileşim
TNSN06403A1 (en)	2008-02-22	3-B-D-RIBOFURANOSYLTHIAZOLO[4,5-d]PYRIDIMINE NUCLEOSIDES AND USES THEREOF
TW200420554A (en)	2004-10-16	A intra-airway administrating preparation
ATE551056T1 (de)	2012-04-15	Mittel zur hemmung der körpergewichtszunahme
ATE326451T1 (de)	2006-06-15	Chinazolin derivate und therapeutische verwendungen davon
WO2008060535A3 (en)	2009-04-09	Use of reversine and analogs for treatment of cancer
GB0623258D0 (en)	2007-01-03	Thiadiazole derivatives for the treatment of neuro-degenerative diseases
EP1695969A4 (de)	2008-11-26	Alpha-aminosäurederivate und deren verwendung als medizin
BRPI0410576A (pt)	2006-06-20	composto quìmico, composição farmacêutica, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, e, método para o tratamento, prevenção ou alìvio de uma doença ou um distúrbio ou condição de um corpo de animal vivo
WO2005000406A3 (en)	2005-06-23	Treatment of amyloid- and epileptogenesis-associated diseases
BR0308911A (pt)	2005-01-04	Composto, composição farmacêutica, métodos de tratamento de dor e de enxaqueca, e, uso de um composto